Personalized Supplements Tested in ALS Using Genomic Disease Subtyping
A Duke-sponsored pilot trial matches ALS patients to targeted supplements based on blood-derived biological pathway signatures.
Summary
ALS is a devastating neurodegenerative disease with very limited treatment options. This Phase 2 pilot trial from Duke University tested whether genomic blood analysis could stratify ALS patients into four biological subtypes — neuroinflammation, oxidative stress, impaired autophagy and axonal transport, and mitochondrial dysfunction — and whether matched supplements could slow disease progression. Participants received one of four supplements: astaxanthin, Protandim, melatonin, or MitoQ, based on their assigned category. The trial ran for nine months, with three months of baseline monitoring followed by six months of supplementation. This precision-medicine approach to ALS is novel and signals a broader shift toward treating neurodegenerative diseases by underlying mechanism rather than diagnosis alone, with direct relevance to aging biology and brain health.
Detailed Summary
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease marked by progressive motor neuron loss. One reason treatments have largely failed may be biological heterogeneity — patients share a diagnosis but differ dramatically in their underlying disease drivers. This Phase 2 pilot trial from Duke University, sponsored by GenieUs, tested a precision-medicine framework to address this problem.
The trial used a proprietary platform called DIGAP (Deep Integrated Genomics Analysis Platform) to analyze blood samples from ALS patients and assign each individual to one of four mechanistic disease categories: neuroinflammation, oxidative stress, impaired autophagy and axonal transport, or mitochondrial dysfunction. Each category mapped to a specific supplement: astaxanthin for neuroinflammation, Protandim (a plant-derived Nrf2 activator) for oxidative stress, melatonin for impaired autophagy, and MitoQ (a mitochondria-targeted antioxidant) for mitochondrial dysfunction.
Participants were monitored for three months before receiving their assigned supplement for six months, allowing for baseline characterization and intra-patient comparison. The trial was designed to be largely virtual and widely inclusive, lowering participation barriers for ALS patients who often have limited mobility.
All four supplements used are well-characterized compounds with established safety profiles and mechanistic rationales in aging and neurodegeneration research. The key innovation is not any individual supplement, but the biological stratification enabling personalized assignment — a model increasingly relevant to age-related disease beyond ALS.
The study is now completed. Results have not been publicly released. Key caveats include pilot-scale size limiting statistical power, the absence of a placebo control described in the abstract, and reliance on a proprietary platform whose validation is not publicly detailed. This summary is based on the abstract only; full methodology and outcomes data remain unavailable.
Key Findings
- ALS patients were stratified into four biological subtypes via blood-based genomic analysis before treatment assignment.
- Four supplements — astaxanthin, Protandim, melatonin, and MitoQ — were matched to specific mechanistic disease categories.
- The trial used a largely virtual design to maximize inclusivity for ALS patients with limited mobility.
- This precision-supplement approach may inform personalized strategies for other neurodegenerative and aging-related diseases.
- The trial is completed, but outcome data have not yet been publicly reported.
Methodology
Phase 2 pilot trial enrolling ALS patients stratified by the DIGAP blood-based genomic platform into four mechanistic subtypes. Participants had three months of monitoring followed by six months of assigned supplement. The trial was largely virtual and sponsored by Duke University in collaboration with GenieUs.
Study Limitations
Summary is based on the abstract only; full methodology, enrollment numbers, and outcome data are not publicly available. The abstract does not describe a placebo control arm, which limits interpretation of any efficacy signals. The DIGAP platform is proprietary and its analytical validation has not been independently published.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: